Claire Hill, solutions support manager at IDBS, explains why advances in technology could be key for helping manufacture cell and gene therapies.
Gene therapy
As innovations in the biopharmaceutical industry continue to push the boundaries of established scientific and engineering practices, the need for faster and more effective process development is greater than ever.
This is especially true for cell and gene therapies, one of the most exciting yet challenging growth areas in recent years. While the therapeutic potential is clear, the technical challenges of manufacturing and the costs involved are still severely limiting. Compared to other products such as monoclonal antibodies, cell and gene therapies are produced in very low volume batches using highly manual processes. An integrated development platform that can connect disparate data sources, support automation, and deliver process and product insight is essential for these niche products to start moving into the mainstream.